logo-loader

Dyadic touts recent collaborations, 3Q highlights at Jefferies London Healthcare Conference

Last updated: 13:05 18 Nov 2019 EST, First published: 08:05 18 Nov 2019 EST

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb and CCO Matthew Jones tell Proactive's Andrew Scott the duo are in London for the Jefferies London Healthcare Conference, the biotech's third year attending. 

Emalfarb and Jones say the Florida-based biotech is touting its recent collaboration with a leading animal health company, as well as its recent 3Q highlights. Dyadic will have a presence later this week at the Protein And Antibody Engineering Summit in Lisbon.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 21 minutes ago